| 20.33 -1.04 (-4.87%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.25 | 1-year : | 32.99 |
| Resists | First : | 24.18 | Second : | 28.25 |
| Pivot price | 19.25 |
|||
| Supports | First : | 18.43 | Second : | 14.88 |
| MAs | MA(5) : | 20.98 |
MA(20) : | 18.75 |
| MA(100) : | 24.13  |
MA(250) : | 33.13 |
|
| MACD | MACD : | 0.3 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 62.3 |
D(3) : | 66 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 65.98 | Low : | 14.88 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SMLR ] has closed below upper band by 38.5%. Bollinger Bands are 24.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.35 - 20.48 | 20.48 - 20.57 |
| Low: | 20.02 - 20.18 | 20.18 - 20.3 |
| Close: | 20.12 - 20.35 | 20.35 - 20.52 |
Semler Scientific, Inc. provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Fri, 16 Jan 2026
Strive completes acquisition of Semler Scientific, triggers Nasdaq delisting - Investing.com
Fri, 16 Jan 2026
Semler Scientific, Inc. (SMLR) Stock Analysis: A Medical Device Innovator with 223% Potential Upside - DirectorsTalk Interviews
Tue, 13 Jan 2026
Bitcoin hoard pushes Strive past Tesla into top 11 corporate holders - Stock Titan
Tue, 13 Jan 2026
Strive (ASST) tumbles 15% on shareholder approval of Semler Scientific (SMLR) acquisition - CoinDesk
Sun, 11 Jan 2026
Semler Scientific Inc. (NASDAQ:SMLR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 15 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 12.1 (%) |
| Held by Institutions | 65.2 (%) |
| Shares Short | 2,760 (K) |
| Shares Short P.Month | 2,400 (K) |
| EPS | 5.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 30.36 |
| Profit Margin | 130.8 % |
| Operating Margin | -72 % |
| Return on Assets (ttm) | -1 % |
| Return on Equity (ttm) | 17.7 % |
| Qtrly Rev. Growth | -44.6 % |
| Gross Profit (p.s.) | 2.19 |
| Sales Per Share | 2.41 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 49.2 % |
| Operating Cash Flow | -27 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | 3.92 |
| PEG Ratio | 0 |
| Price to Book value | 0.66 |
| Price to Sales | 8.41 |
| Price to Cash Flow | -11.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|